CN1380339A - 一种突变的人基因核苷酸序列编码多肽 - Google Patents
一种突变的人基因核苷酸序列编码多肽 Download PDFInfo
- Publication number
- CN1380339A CN1380339A CN 01105946 CN01105946A CN1380339A CN 1380339 A CN1380339 A CN 1380339A CN 01105946 CN01105946 CN 01105946 CN 01105946 A CN01105946 A CN 01105946A CN 1380339 A CN1380339 A CN 1380339A
- Authority
- CN
- China
- Prior art keywords
- sequence
- tumor necrosis
- human tumor
- relevant
- apoptosis induction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 13
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 11
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 title claims description 15
- 230000000869 mutational effect Effects 0.000 title abstract 2
- 239000002773 nucleotide Substances 0.000 title description 3
- 125000003729 nucleotide group Chemical group 0.000 title description 3
- 239000003446 ligand Substances 0.000 claims abstract description 17
- 239000002299 complementary DNA Substances 0.000 claims abstract description 15
- 230000006907 apoptotic process Effects 0.000 claims description 27
- 241000894006 Bacteria Species 0.000 claims description 26
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 claims description 26
- 230000006698 induction Effects 0.000 claims description 23
- 235000001014 amino acid Nutrition 0.000 claims description 20
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 14
- 238000012217 deletion Methods 0.000 claims description 11
- 230000037430 deletion Effects 0.000 claims description 11
- 239000013613 expression plasmid Substances 0.000 claims description 11
- 102000057041 human TNF Human genes 0.000 claims description 11
- 239000006228 supernatant Substances 0.000 claims description 11
- 239000000047 product Substances 0.000 claims description 10
- 238000001962 electrophoresis Methods 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 8
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 238000012408 PCR amplification Methods 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 210000003000 inclusion body Anatomy 0.000 claims description 6
- 108091008146 restriction endonucleases Proteins 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 5
- 230000000968 intestinal effect Effects 0.000 claims description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000013461 design Methods 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 108010064696 N,O-diacetylmuramidase Proteins 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 3
- 239000004202 carbamide Substances 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 230000004087 circulation Effects 0.000 claims description 3
- 238000010367 cloning Methods 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 239000000287 crude extract Substances 0.000 claims description 3
- 238000013016 damping Methods 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 238000001556 precipitation Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 238000004153 renaturation Methods 0.000 claims description 3
- 238000011144 upstream manufacturing Methods 0.000 claims description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 239000003560 cancer drug Substances 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 abstract description 18
- 230000001939 inductive effect Effects 0.000 abstract description 8
- 206010028980 Neoplasm Diseases 0.000 abstract description 6
- 230000034994 death Effects 0.000 abstract description 3
- 108700012411 TNFSF10 Proteins 0.000 description 23
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 7
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000005477 standard model Effects 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002689 xenotransplantation Methods 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010047956 Nucleosomes Proteins 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 101710097160 Tumor necrosis factor ligand superfamily member 10 Proteins 0.000 description 1
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000003145 cytotoxic factor Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 230000028974 hepatocyte apoptotic process Effects 0.000 description 1
- 102000054896 human PML Human genes 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000001623 nucleosome Anatomy 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB01105946XA CN1172956C (zh) | 2001-04-10 | 2001-04-10 | 一种突变的人肿瘤坏死因子相关凋亡诱导配体多肽及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB01105946XA CN1172956C (zh) | 2001-04-10 | 2001-04-10 | 一种突变的人肿瘤坏死因子相关凋亡诱导配体多肽及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1380339A true CN1380339A (zh) | 2002-11-20 |
CN1172956C CN1172956C (zh) | 2004-10-27 |
Family
ID=4655007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB01105946XA Expired - Lifetime CN1172956C (zh) | 2001-04-10 | 2001-04-10 | 一种突变的人肿瘤坏死因子相关凋亡诱导配体多肽及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1172956C (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100497381C (zh) * | 2004-08-06 | 2009-06-10 | 中国人民解放军军事医学科学院生物工程研究所 | Muc1及其C端活性片段突变体,它们的编码基因与应用 |
CN102250254A (zh) * | 2010-05-19 | 2011-11-23 | 江苏先声药物研究有限公司 | 肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用 |
CN102898526A (zh) * | 2011-07-28 | 2013-01-30 | 山东先声麦得津生物制药有限公司 | 一种肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用 |
CN105461801A (zh) * | 2015-11-09 | 2016-04-06 | 中国药科大学 | 高活性肿瘤坏死因子相关凋亡诱导配体的突变体 |
CN106591449A (zh) * | 2016-12-13 | 2017-04-26 | 成都地奥九泓制药厂 | 预测肿瘤对trail类似物敏感性的方法 |
CN111592601A (zh) * | 2011-07-06 | 2020-08-28 | 江苏靶标生物医药研究所有限公司 | 一种肿瘤靶向性肿瘤坏死因子相关凋亡配体变体及其应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1958794B (zh) * | 2005-11-03 | 2010-05-05 | 成都地奥九泓制药厂 | 人肿瘤坏死因子相关凋亡诱导配体突变体编码cDNA及制备方法和应用 |
-
2001
- 2001-04-10 CN CNB01105946XA patent/CN1172956C/zh not_active Expired - Lifetime
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100497381C (zh) * | 2004-08-06 | 2009-06-10 | 中国人民解放军军事医学科学院生物工程研究所 | Muc1及其C端活性片段突变体,它们的编码基因与应用 |
CN102250254A (zh) * | 2010-05-19 | 2011-11-23 | 江苏先声药物研究有限公司 | 肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用 |
CN111592601A (zh) * | 2011-07-06 | 2020-08-28 | 江苏靶标生物医药研究所有限公司 | 一种肿瘤靶向性肿瘤坏死因子相关凋亡配体变体及其应用 |
CN102898526A (zh) * | 2011-07-28 | 2013-01-30 | 山东先声麦得津生物制药有限公司 | 一种肿瘤坏死因子相关凋亡诱导配体融合蛋白及其制备和应用 |
CN105461801A (zh) * | 2015-11-09 | 2016-04-06 | 中国药科大学 | 高活性肿瘤坏死因子相关凋亡诱导配体的突变体 |
CN105461801B (zh) * | 2015-11-09 | 2019-03-05 | 中国药科大学 | 高活性肿瘤坏死因子相关凋亡诱导配体的突变体 |
CN106591449A (zh) * | 2016-12-13 | 2017-04-26 | 成都地奥九泓制药厂 | 预测肿瘤对trail类似物敏感性的方法 |
CN106591449B (zh) * | 2016-12-13 | 2020-09-22 | 成都地奥九泓制药厂 | 预测肿瘤对trail类似物敏感性的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1172956C (zh) | 2004-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Müller et al. | Superior serum half life of albumin tagged TNF ligands | |
KR102508182B1 (ko) | 형질전환 대식세포, 키메라 항원 수용체, 및 관련 방법 | |
IE58709B1 (en) | Purification, production and use of tumor necrosis factors | |
Xie et al. | Identification and functional characterization of the goldfish (Carassius auratus L.) high mobility group box 1 (HMGB1) chromatin-binding protein | |
Huo et al. | Functional characterization of interleukin (IL)-22 and its inhibitor, IL-22 binding protein (IL-22BP) in Mandarin fish, Siniperca chuatsi | |
Xiao et al. | Tumor necrosis factor-alpha gene from mandarin fish, Siniperca chuatsi: molecular cloning, cytotoxicity analysis and expression profile | |
WO2021190551A1 (zh) | 结合cd19的嵌合抗原受体及其用途 | |
CN108484776B (zh) | 一种融合蛋白、制备方法及其应用 | |
CN1380339A (zh) | 一种突变的人基因核苷酸序列编码多肽 | |
KR20000071226A (ko) | 간세포 암의 예방 및 치료 방법 | |
CN108264548B (zh) | 鳜鱼伽玛干扰素相关因子及其重组蛋白和应用 | |
CN102180961B (zh) | 黑青斑河鲀干扰素IFNγ2及其制备方法和应用 | |
EP1465912A2 (en) | Novel chimeric tnf ligands | |
CN1381583A (zh) | 人乳头瘤病毒e6/e7融合基因及其高效表达载体和融合蛋白疫苗 | |
CN1314805C (zh) | 一种新型促细胞凋亡素(apo)及其抗体,制备及用途 | |
CN103382220A (zh) | 具有抗感染、抗肿瘤活性的细胞因子fam19a4及其应用 | |
Liu et al. | TroTNFSF6, a tumor necrosis factor ligand superfamily member, promotes antibacterial immune response of golden pompano, Trachinotus ovatus | |
CN1017626B (zh) | 生产新的细胞生长调节因子的方法 | |
CN115286698A (zh) | 抗原短肽用于筛选治疗与hpv相关的疾病的药物中的用途及其筛选的tcr | |
Ebina et al. | Antitumor effect of PSK at a distant site: inductions of interleukin‐8‐like factor and macrophage chemotactic factor in murine tumor | |
CN107266553A (zh) | 高效人白细胞介素ⅱ突变体融合蛋白及其应用 | |
CN102206281B (zh) | 融合蛋白tetph、表达载体及其构建方法 | |
CN101066993B (zh) | 重组金黄色葡萄球菌肠毒素m及制备和应用 | |
CN108785658A (zh) | Hvem蛋白作为药物在治疗与肝损伤相关的疾病中的应用 | |
CN113925876B (zh) | Cik免疫细胞在治疗癌症中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: CHENGDU DIAO 9 WANG PHARMACEUTICAL FACTORY Free format text: FORMER OWNER: CHENGDU DIAO PHARMACEUTICAL GROUP CO., LTD. Effective date: 20090417 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090417 Address after: High tech Zone of Chengdu City, Sichuan Province, Gaopeng Road No. 16 Patentee after: Chengdu Diao Jiuhong Pharmaceutical Factory Address before: No. 26, hi tech Road, hi tech Zone, Sichuan, Chengdu Patentee before: Diao Pharmaceutical Group Co., Ltd., Chengdu |
|
CX01 | Expiry of patent term |
Granted publication date: 20041027 |
|
CX01 | Expiry of patent term |